Last reviewed · How we verify

Diabetes mellitus — Treatment Landscape & Competitive Intelligence

Diabetes mellitus (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Diabetes mellitus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tresiba INSULIN DEGLUDEC Novo Nordisk Insulin Analog [EPC] Insulin receptor 2015-01-01
Levemir INSULIN DETEMIR Novo Nordisk Insulin Analog [EPC] Insulin receptor 2005-01-01
Apidra INSULIN GLULISINE Sanofi Insulin Analog [EPC] Insulin receptor 2004-01-01
Novolog INSULIN ASPART Novo Nordisk Insulin Analog [EPC] Insulin receptor 2000-01-01
Levemir Levemir The Royal Bournemouth Hospital Insulin receptor
Apidra Apidra Kinderkrankenhaus auf der Bult Insulin receptor
Novolog Novolog Massachusetts General Hospital Insulin receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Novo Nordisk · 3 drugs in Diabetes mellitus
  2. Kinderkrankenhaus auf der Bult · 1 drug in Diabetes mellitus
  3. Massachusetts General Hospital · 1 drug in Diabetes mellitus
  4. Sanofi · 1 drug in Diabetes mellitus
  5. The Royal Bournemouth Hospital · 1 drug in Diabetes mellitus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Diabetes mellitus:

Cite this brief

Drug Landscape (2026). Diabetes mellitus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diabetes-mellitus. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing